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itamin C and Percutaneous
oronary Intervention*
atrice Delafontaine, MD, Asif Anwar, MD
ew Orleans, Louisiana
ercutaneous coronary intervention (PCI) is associated with
15% to 35% incidence of periprocedural myocardial injury
PMI). Its spectrum ranges from obvious clinical myocardial
nfarction to subtle myocardial injury manifested by mild
ises in cardiac enzymes. Even in the latter case, the
esulting myocardial damage is clinically important, as
ultiple studies have consistently demonstrated that PMI is
ssociated with increased long-term mortality with a graded
isk related to the extent of creatine kinase-MB or cardiac
roponin elevation. Despite extensive basic and clinical
esearch and multiple therapeutic approaches, its incidence
as not substantially decreased over the last 2 decades. Two
atterns of PMI have been recognized by magnetic reso-
ance imaging. Type I is near the intervention site conse-
uent to side branch occlusion, and type II is in the
ownstream territory of the treated artery where perfusion is
ompromised mainly due to structural and functional mi-
rovascular dysfunction (1). PCI can be considered as an
atrogenic form of plaque rupture. It magnifies underlying
r pre-existing microvascular disorders. It is thus not sur-
rising that patients with pre-procedural abnormal coronary
ow (2), high cardiovascular risk profiles, or high systemic
nflammation markers, such as high sensitivity C-reactive
rotein, are most likely to have PMI and worse long-term
utcomes (3).
See page 221
Mechanisms of reduced microvascular perfusion after
CI are incompletely understood. Mechanical obstruction
f the microvasculature due to plaque-derived emboli has
een recognized in autopsy studies as a component of this
yndrome (4). These microvascular plugs are formed by
theromatous debris, cholesterol clefts, apoptotic bodies,
icroparticles, platelets, neutrophils, sludge, or thrombus.
owever, the use of distal protection devices, anticoagula-
ion, and powerful glycoprotein IIb/IIIa inhibitors does not
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-v
ions or the American College of Cardiology.
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ther important mechanisms might be responsible for the
ismatch between myocardial oxygen supply and demand.
hese include abnormal vasoreactivity, coagulation, inflam-
ation, immunologic stimulation, neurohumoral activation,
nd oxidative stress (1). The acute trigger of these mecha-
isms is putatively linked to the downstream effect of
iologically active molecules in the setting of an already
ompromised baseline microcirculatory function. Thus, nu-
erous studies have demonstrated abnormal vasoreactivity
n atherosclerosis characterized by impaired coronary blood
ow in response to endothelium-dependent vasodilators.
he presence of endothelial dysfunction as assessed by
easurement of coronary flow reserve or by forearm blood
ow studies is a strong predictor of future cardiovascular
vents (5). Increased oxidative stress via its ability to reduce
itric oxide bioavailability plays a crucial role in endothelial
ysfunction and has been proposed to contribute to mech-
nisms of PMI.
PCI has been associated with an increase in oxidative
tress as assessed by elevated coronary or systemic venous
evels of F2-isoprostane (6). The F2-isoprostane family, and
otably 8-iso-prostaglandin F2-alpha (8-iso-PGF2alpha), are
rostaglandin isomers formed by free radical–mediated
xidation of arachidonic acid in the membranes’ phospho-
ipids. Although they have inherent vasoconstrictor effects
nd are elevated after PCI, their role in PMI is unclear. In
nimal models of infarction/reperfusion inhibition of iso-
rostane F2alpha III failed to improve reflow (7). However,
ncreased concentrations of circulating F2-isoprostanes have
een associated with coronary calcification (8) or markers of
nflammation and endothelial dysfunction in young healthy
dults in the CARDIA (Coronary Artery Risk Develop-
ent in Young Adults) study (9). Thus, there is evidence
hat levels of isoprostane F2 reflect overall redox status.
In this regard, the findings of Basili et al. (10), in this
ssue of JACC: Cardiovascular Interventions, that intrave-
ous ascorbic acid (vitamin C) infusion improves myocar-
ial perfusion grade during elective PCI are noteworthy.
heir working hypothesis is that vitamin C, by quenching
ree radicals, decreases myocardial oxidative stress and
mproves myocardial microcirculation. In this prospective
lacebo-controlled study, patients with stable angina and de
ovo 1-vessel disease were assigned to receive 1 g of ascorbic
cid or placebo before PCI. Markers of oxidative stress that
ere measured in venous blood before and after the proce-
ure included 8-iso-PGF2alpha and 8-hydroxy-2-
eoxyguanosine (8-OHdG), a product of hydroxyl radical–
eoxyribonucleic acid interaction (11). The corrected
hrombolysis In Myocardial Infarction (TIMI) frame
ount, when compared with baseline values, as expected,
mproved in both arms after coronary revascularization.
owever, this improvement was significantly better in the
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231roup achieving lower-risk corrected TIMI frame count
lass (p  0.0001). Similarly, microvascular perfusion as
ssessed by TIMI myocardial perfusion grade improved to a
reater extent in the treated group. Thus, 79% of individuals
eceiving vitamin C reached TIMI myocardial perfusion
rade III versus 39% in controls. This improvement corre-
ated with reduced oxidative stress markers, whereas, in the
lacebo group, these were significantly higher than baseline.
ven though the increase in cardiac troponin levels was the
ame in control subjects and treated patients, the data
uggest that vitamin C improved microcirculatory function,
otentially via its antioxidant effects. It is of note that the
alf-life of parenteral vitamin C is short, and one can
peculate about whether continued vitamin C administra-
ion during PCI would have produced an improved effect.
Basili et al. (10) correctly point out that decreased
2-isoprostanes can only putatively be linked to decreased
yocardial oxidative stress. Furthermore, the potential role
f reduced oxidative stress in the vitamin C induced
mprovement in TIMI myocardial perfusion grade cannot
e established from this study. Quantitative measurements
f reactive oxygen species and reactive nitrogen species are
ifficult in vivo and decreases of these lipid peroxidation end
roducts may not reflect actual decreases in free radical
eneration. It is of note that Guan et al. (12) did not find a
eduction in urinary 8-epi-PGalpha levels after PCI in
atients with acute myocardial infarction after infusion of
g of vitamin C. It is also relevant to note that despite
ncreasing evidence for the association between increased
xidative stress and cardiovascular disease (13), the results of
linical trials of antioxidant therapy such as vitamin C have
een mixed to negative (14). One potential explanation for
hese results is that scavenger activity of vitamin C is
ependent on serum concentrations of 1 to 10 mmol/l or
igher (15), which are not achieved with chronic adminis-
ration. Furthermore, vitamin C has been reported to have
aradoxical pro-oxidant effects (16).
The association of F2-isoprostane levels and cardiovascu-
ar outcomes is also not straightforward. Thus, in a setting
f patients undergoing elective PCI, Berg et al. (17) did not
nd any correlation between 8-iso-PGF2alpha and post-PCI
yocardial injury as defined by troponin release. Chronic
dministration of alpha-tocopherol (vitamin E) to individ-
als with coronary artery disease decreased inflammatory
arameters such as high sensitivity C-reactive protein and
educed indices of oxidant stress such as urinary F2-
soprostanes but failed to alter carotid intimal media thick-
ess or cardiovascular events over 2 years (18). Similarly,
itamin C and E therapy reduced F2-isoprostanes in high-
isk individuals but failed to alter oxidized low-density
ipoproteins or autoantibodies to oxidized low-density li-
oproteins, or to improve endothelial vasomotor function
ver 6 months (19). On the contrary, omega-3 infusion in
n animal model of cardiac ischemia-reperfusion injury
1ignificantly reduced infarct size, and this correlated with a
arked reduction in serum markers of oxidative stress,
amely 8-isoprostanes (20). Furthermore, compared with
lacebo, oral administration of an inhibitor of xanthine
xidase, allopurinol, to patients with acute myocardial
nfarction undergoing PCI was also associated with reduced
rinary 8-epi-PGF2alpha with less coronary flow perturba-
ion and improved left ventricular ejection fraction at 6
onths (21). This latter study suggested that inhibiting the
eneration of oxygen-derived radicals during reperfusion
herapy is beneficial to left ventricular function.
In summary, published data on potential beneficial effects
f antioxidants on PMI are sparse and mixed. At the least,
he interesting study of Basili et al. (10) is hypothesis-
enerating and will provide a rationale to further test the
ffect of antioxidants in the setting of coronary revascular-
zation procedures.
eprint requests and correspondence: Dr. Patrice Delafontaine,
ulane University Heart and Vascular Institute, 1430 Tulane
venue, SL 48, New Orleans, Louisiana 70112. E-mail: pdelafon@
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